RE:Q3 OutlookLike your analysis Rock. Although I think you might be a little optimistic in that there maybe more costs that creep in such as costs to ramp up new surgeons and lingering marketing costs that I would hope is done now and they can reduce. But never the less i think your in the ballpark. Couple of other numbers to consider looking at balance sheet. If you calculate NAV using assets-goodwill-liabilities (6.7M) and then divide by number of shares outstanding (36.8M) you get 0.18 per share. A share price of 0.415 means trading at 2.3 x NAV at the close today. I not sure where to compare this with, but for a company with a clear growth strategy, seems very reasonable valuation with room to expand if growth and profit come through. Also. if things work out in the coming quarters and we see a 0.05 EPS result and an annual forward EPS at about 0.20 then a conservative PE of 4 would mean an 0.80 stock (doubling from here). This could get better with traction in their growth and earnings. Given they have no real debt to worry about I like the risk/reward of buying this dip. It all comes down to management and execution.. will their marketing campaign be effective and yield results in the second half, can they now reduce costs in marketing, can they manage their costs well as they ramp up new surgeons, and return to profit. I hope so as I am inclined to buy here.